OMX-0407

OMX-0407 is an orally available, first-in-class spectrum-selective kinase inhibitor developed for the treatment of solid tumors that cannot be surgically removed. It primarily targets and inhibits salt-inducible kinase 3 (SIK3), a novel epigenetic modulator implicated in cancer cell proliferation and survival. By blocking SIK3 and other key oncology-relevant tyrosine kinases, OMX-0407 disrupts signaling cascades essential for tumor cell division and growth. The drug acts through a dual mechanism—directly inducing G1-phase cell cycle arrest in tumor cells by inhibiting Src-family kinase activity, and sensitizing the tumor microenvironment to immune-mediated killing by potentiating apoptosis in response to death receptor ligands such as TNF. Preclinical studies have shown robust anti-tumor efficacy in models of angiosarcoma, renal cell carcinoma, breast cancer, lung cancer, colorectal carcinoma, and melanoma. Clinical trials are ongoing for several solid tumor indications including kidney cancer (renal cell carcinoma), angiosarcoma, non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), urothelial cancer, sarcoma, and others.

Other names

OMX 0407OMX0407OMX-0407IMT 07IMT07IMT-07